10-KPeriod: FY2023

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2023

Filed February 22, 2024For Securities:GH

Summary

Guardant Health, Inc. reported a total revenue of $563.9 million for the year ended December 31, 2023, a 25% increase year-over-year, driven primarily by a 31% rise in precision oncology testing revenue. Despite this top-line growth, the company continued to incur significant net losses, amounting to $479.4 million for the year. The company has a substantial cash and cash equivalents balance of $1.1 billion as of December 31, 2023, which it believes is sufficient to fund its operations for more than 12 months. The company is focused on expanding its product portfolio and market adoption, particularly with its Shield test for early cancer detection, for which a PMA was submitted to the FDA. However, significant risks remain, including the company's ongoing unprofitability, dependence on third-party payer coverage and reimbursement, and intense competition in the precision oncology market. A recent jury verdict in a patent infringement case resulted in an $83.4 million liability accrual, which is a significant concern for investors.

Financial Highlights

55 data points
Beta

Revenue

$563.95M

59.7% Gross Margin

Net Income

-$479.40M

-85.0% Net Margin

EPS (Diluted)

$-4.28

Total Assets

$1.79B

Cash & Equivalents

$1.13B

Free Cash Flow

-$345.46M

Financial Statements
Beta
Revenue$563.95M
Cost of Revenue$227.05M
Gross Profit$336.90M
R&D Expenses$367.19M
Operating Expenses$1.13B
Operating Income-$564.73M
Interest Expense$2.58M
Net Income-$479.40M
EPS (Basic)$-4.28
EPS (Diluted)$-4.28
Shares Outstanding (Basic)111.99M
Shares Outstanding (Diluted)111.99M

Key Highlights

  • 1Total revenue increased by 25% to $563.9 million in 2023, driven by strong growth in precision oncology testing.
  • 2Precision oncology testing revenue grew by 31% year-over-year, indicating increasing adoption of the company's diagnostic solutions.
  • 3The company continues to operate at a net loss, reporting a loss of $479.4 million for the year ended December 31, 2023.
  • 4Guardant Health maintained a strong liquidity position with $1.1 billion in cash and cash equivalents as of December 31, 2023, providing over 12 months of operational runway.
  • 5The Shield test for early cancer detection has shown promising results, with a PMA submitted to the FDA, and the company is also expanding into lung cancer screening.
  • 6Significant litigation risk exists, with an $83.4 million liability accrued due to a patent infringement jury verdict, which the company is contesting.
  • 7The company faces ongoing challenges related to payer coverage, reimbursement, and intense competition within the precision oncology market.

Frequently Asked Questions

In 2023, Guardant Health reported total revenue of $563.9 million, an increase of 25% compared to 2022, driven primarily by growth in precision oncology testing. However, the company incurred a net loss of $479.4 million.

The primary growth driver is the increasing adoption of its precision oncology tests, particularly Guardant360, by both clinical customers and biopharmaceutical companies. The company is also investing heavily in new product development, such as the Shield test for early cancer detection, and expanding its international presence.

Key risks include the company's ongoing net losses and path to profitability, reliance on third-party payer coverage and reimbursement rates, intense competition in the diagnostics market, potential regulatory changes, and significant legal risks, such as the recently accrued $83.4 million liability from a patent infringement verdict.

Guardant Health ended 2023 with $1.1 billion in cash and cash equivalents, which it believes is sufficient to fund operations for over 12 months. The company has also raised capital through equity offerings in 2023. It continues to monitor its liquidity and may seek additional capital if needed.